Request a copy

Full Text

• Desreux J, Gaspard U, Bleret V, et al. - Le cancer du sein en Belgique: pourquoi sommes-nous les premiers en Europe? Rev Med Liege, 2011, 66, 231-237.
• Cardoso F, Costa A, Norton L, et al. - 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast, 2012, 21, 242-252.
• Cardoso F, Harbeck N, Fallowfield L, et al. - Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012, 23 Suppl 7, vii11-vii19.
• http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf, NCCN Clinical Practice Guidelines: Breast Cancer v3, 2014, consulté le 17/5/2014
• Chia S, Gradishar W, Mauriac L, et al. - Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol, 2008, 26, 1664-1670.
• Johnston SR, Kilburn LS, Ellis P, et al. - Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptorpositive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol, 2013, 14, 989-998.
• Osborne CK, Wakeling A, Nicholson RI. - Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer, 2004, 90 Suppl 1, S2-S6.
• Gennigens C, Sautois B, Jerusalem G. - Evérolimus (RAD001/Afinitor®) dans le traitement du cancer du rein métastatique. Rev Med Liege, 2010, 65, 212-216.
• Yao JC, Shah MH, Ito T, et al. - Everolimus for advanced pancreatic neuroendocrine tumors. New England J Med, 2011, 364, 514-523.
• Arrêté Ministériel du 16/7/2013. Moniteur belge du 19/7/13, 2013, 45449-45480.
• Yamnik RL, Holz MK. - mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett, 2010, 584, 124-128.
• Yamnik RL, Digilova A, Davis DC, et al. - S6 kinase I regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem, 2009, 284, 6361-6369.
• Ellard SL, Clemons M, Gelmon KA, et al. - Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol, 2009, 27, 4536-4541.
• Baselga J, Semiglazov V, Van Dam P, et al. - Phase II randomized study of neoadjuvant évérolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol, 2009, 27, 2630-2637.
• Bachelot T, Bourgier C, Cropet C, et al. - Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol, 2012, 30, 2718-2724.
• Baselga J, Campone M, Piccart M, et al. - Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 2012, 366, 520-529.
• Yardley DA, Noguchi S, Pritchard KI, et al. - Everolimus Plus Exemestane in Postmenopausal Patients with HR (+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Adv Ther, 2013, 30, 870-884.
• Campone M, Bachelot T, Gnant M, et al. - Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer, 2013, 49, 2621-2632.
• Pritchard KI, Burris HA, III, Ito Y, et al - Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer, 2013, 13, 421-432.
• Piccart M, Hortobagyi GN, Campone M, et al. - Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2. Eur J Cancer, 2014, 50, Suppl 3, S1.
• Treilleux I, Arnedos M, Cropet C, et al. - Predictive markers of everolimus efficacy in hormone receptor positive (HR+) metastatic breast cancer (MBC): final results of the TAMRAD trial translational study. J Clin Oncol, 2013, 31, Suppl 15, abst 510.
• Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, et al. - Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol, 2013, 31, Suppl 15, abst LBA509.
• Burris HA, III, Lebrun F, Rugo HS, et al. - Healthrelated quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer, 2013, 119, 1908-1915.
• Aapro M, Andre F, Blackwell K, et al. - Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol, 2014, 25, 763-773.
• http://clinicaltrials.gov/ct2/show/NCT01805271?term=NCT01805271&rank=1 Consulté le 13/05/2014.
• http://clinicaltrials.gov/ct2/show/NCT01674140?term=NCT01674140&rank=1 Consulté le 13/05/2014.
• http://clinicaltrials.gov/ct2/show/NCT01698918?term=NCT01698918&rank=1 Consulté le 13/05/2014.
• http://clinicaltrials.gov/ct2/show/NCT01633060?term=NCT01633060&rank=1 Consulté le 13/05/2014.
• Van Cutsem E, Tabernero J, Lakomy R, et al. - Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol, 2012, 30, 3499-3506.
• Morrow PK, Wulf GM, Ensor J, et al. - Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol, 2011, 29, 3126-3132.
• Andre F, Campone M, O'Regan R, et al. - Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol, 2010, 28, 5110-5115.
• Hurvitz SA, Dalenc F, Campone M, et al. - A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat, 2013, 141, 437-446.
• Jerusalem G, Fasolo A, Dieras V, et al. - Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat, 2011, 125, 447-455.
• Andre F, O'Regan R, Ozguroglu M, et al. - Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 2014, 15, 580-591.
• Jerusalem G, Andre F, Chen D, et al. - Evaluation of everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway: exploratory biomarker observations from the BOLERO-3 trial. Eur J Cancer, 2013, 49, PS8.
• http://clinicaltrials.gov/ct2/show/NCT00876395?term=NCT00876395&rank=1 Consulté le 13/05/2014.